Adrenocortical carcinoma (ACC) · line 1 · Mitotane adjuvant monotherapy (ACC)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | standard |
| Linked regimen | REG-MITOTANE-ADJUVANT-ACC |
| ID | IND-ACC-1L-RESECTION-MITOTANE |
|---|---|
| Type | Indication |
| Status | reviewed 2026-07-11 | pending_clinical_signoff |
| Diseases | DIS-ADRENOCORTICAL-CARCINOMA |
| Sources | SRC-ADIUVO-TERZOLO-2023 SRC-ENSAT-ACC-2018 SRC-ESMO-ACC-2020 SRC-NCCN-NET-2025 |
Notes
STUB pending clinical co-lead sign-off (CHARTER §6.1). Authored to close the DIS-ADRENOCORTICAL-CARCINOMA v0.1 content gap (metadata.awaiting_proposal). "High recurrence risk" is operationalized via RF-ACC-HIGH-RECURRENCE-RISK-BIOLOGY (stage III / Ki-67 >10% / R1-RX margin), itself a first-pass reading of ADIUVO's low/intermediate-risk enrollment criteria in reverse — pending clinical co-lead confirmation against the primary ENSAT/ESMO guideline text, which may specify additional risk factors (e.g. tumor rupture, vascular invasion) not yet encoded. Lower-risk resected patients (surveillance-alone candidates per ADIUVO) are intentionally NOT covered by this Indication — see ALGO-ACC-1L step 2 null-branch. Surgery is described in prose (rationale/stage_requirements) rather than via a Surgery-entity FK/ phases: structure — no adrenalectomy Surgery entity exists in this KB and authoring one is out of scope for this task.
Used By
Algorithms
ALGO-ACC-1L- ALGO-ACC-1L
Drug
DRUG-MITOTANE- Mitotane
Sources
SRC-ADIUVO-TERZOLO-2023- Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (A...